Sol-Gel Technologies Price to Free Cash Flow Ratio 2016-2025 | SLGL
Historical price to free cash flow ratio values for Sol-Gel Technologies (SLGL) since 2016.
| Sol-Gel Technologies Price to Free Cash Flow Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM FCF per Share | Price to FCF Ratio |
| 2026-05-11 | 69.98 | 0.00 | |
| 2025-12-31 | 42.14 | 0 | 0.00 |
| 2025-09-30 | 29.15 | $-4.98 | 0.00 |
| 2025-06-30 | 7.40 | $-2.04 | 0.00 |
| 2025-03-31 | 5.20 | $-4.98 | 0.00 |
| 2024-12-31 | 9.30 | $-4.98 | 0.00 |
| 2024-09-30 | 6.80 | $-6.57 | 0.00 |
| 2024-06-30 | 8.90 | $-6.29 | 0.00 |
| 2024-03-31 | 9.80 | $-6.57 | 0.00 |
| 2023-12-31 | 11.05 | $-6.57 | 0.00 |
| 2023-09-30 | 16.30 | $-4.17 | 0.00 |
| 2023-06-30 | 29.90 | $-4.31 | 0.00 |
| 2023-03-31 | 38.80 | $-4.17 | 0.00 |
| 2022-12-31 | 45.60 | $-4.17 | 0.00 |
| 2022-09-30 | 50.20 | $-3.40 | 0.00 |
| 2022-06-30 | 41.00 | $-1.31 | 0.00 |
| 2022-03-31 | 73.80 | $-3.40 | 0.00 |
| 2021-12-31 | 74.00 | $-3.40 | 0.00 |
| 2021-09-30 | 100.00 | $-11.38 | 0.00 |
| 2021-06-30 | 123.80 | $-12.00 | 0.00 |
| 2021-03-31 | 123.80 | $-11.38 | 0.00 |
| 2020-12-31 | 97.90 | $-11.38 | 0.00 |
| 2020-09-30 | 72.40 | $-11.82 | 0.00 |
| 2020-06-30 | 89.53 | $-9.24 | 0.00 |
| 2020-03-31 | 70.60 | $-11.82 | 0.00 |
| 2019-12-31 | 171.50 | $-11.82 | 0.00 |
| 2019-09-30 | 89.90 | $-4.69 | 0.00 |
| 2019-06-30 | 91.06 | $-11.60 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.210B | $0.019B |
| Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |